



## PPD Launches New Global Biostatistics Technology Infrastructure

### Increases company's ability to deliver secure, timely clinical trial data

**WILMINGTON, N.C.** (December 2, 2009) - PPD, Inc. (Nasdaq: PPD) today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company's ability to deliver secure, quality reporting and data analysis to meet client timelines.

The virtual server environment allows PPD to deploy global teams of biostatisticians and programmers to projects on a single platform. The analysis processing environments are located in the same data centers as PPD's [clinical data management](#) systems, eliminating the need to move large quantities of data between file servers. Operating on this unified platform reduces bandwidth utilization, increases employee productivity and creates significant time savings.

"This new environment allows our employees around the world to work together, accessing the same data," said Susan Atkinson, senior vice president, global biometrics and technical operations for PPD. "Our investment in a global, innovative solution decreases our computer processing time and enhances our data security, giving us the ability to deliver more efficiently for our clients."

In addition, the BTI features a number of best practice global solutions such as code development, version control, output configuration, validation and delivery of production output. PPD has installed the BTI at its U.S. locations in Austin, Texas, and Research Triangle Park, N.C., as well as at its European headquarters in Cambridge, U.K.

PPD employs approximately 300 biostatisticians and programmers worldwide who provide study design, planning and reporting expertise across all phases of drug development. The company's reporting services range from Phase I trials through regulatory submission and post approval and include full support of the Clinical Data Interchange Standards Consortium data standards.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 38 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at <http://www.ppd.com>.

*Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the value of the biostatistics technology infrastructure, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; the ability to attract and retain key personnel; competition within the outsourcing industry; risks associated with investments, such as impairments; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.*

#### Contacts

Media:

Sue Ann Pentecost

+1 919 456 5890

[sueann.pentecost@ppdi.com](mailto:sueann.pentecost@ppdi.com)

Analysts/Investors:

Luke Heagle

+1 910 558 7585

[luke.heagle@ppdi.com](mailto:luke.heagle@ppdi.com)